The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

NCT06012448 | Completed Phase 4 FDA Drug

• 1 other identifier: HUM00227361
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.

Conditions

Dermal Hypersensitivity Reaction

Keywords

Skin rash; Dupilumab; Skin biopsies

Outcome Measures

Primary Outcomes (1)

• Change in Th2 immune cell population in lesional Dermal hypersensitivity reaction (DHR) skin at week 16 compared to week 0.

  Week 0, week 16

Secondary Outcomes (16)

• Changes in Total Body surface area (TBSA) in patients with DHR treated with dupilumab at week 2 from week 0.

  Week 0, week 2

• Changes in Total Body surface area in patients with DHR treated with dupilumab at week 8 from week 0.

  Week 0, week 8

• Changes in Total Body surface area in patients with DHR treated with dupilumab at week 16 from week 0.

  Week 0, week 16

• Changes in Total Body surface area in patients with DHR treated with dupilumab at week 24 from week 0.

  Week 0, week 24

• Changes in Investigator Global Assessment (IGA) in patients with DHR treated with dupilumab at week 2 from week 0.

  Week 0, 2 weeks

Study Arms (1)

Dupilumab

EXPERIMENTAL

All patients will receive dupilumab.

Drug: Dupilumab

Interventions

Dupilumab DRUG

Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24. In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks.

Also known as: Dupixent

Dupilumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Established diagnosis of chronic idiopathic DHR as defined by presence of clinical and histopathologic features of DHR for at least 6 weeks without an underlying cause or associated trigger
• Moderate-to-severe DHR as defined by greater or equal 5% total body-surface-area (TBSA) involvement and IGA of greater or equal to 3.
• Female subjects of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree either to commit to true abstinence throughout the study and for 12 weeks after the last study drug injection, when this is in line with the preferred and usual lifestyle of the subject, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.
• Subject willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol.

You may not qualify if:

• Subjects meeting 1 or more of the following criteria at screening or baseline:
• Had an exacerbation of asthma requiring hospitalization in the preceding 12 months.
• Reporting asthma that has not been well-controlled (ie, symptoms occurring on \>2 days per week, nighttime awakenings 2 or more times per week, or some interference with normal activities) during the preceding 3 months.
• Subjects with a current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis.
• Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.
• Confirmed or suspected COVID-19 infection within 4 weeks before the screening or baseline visit.
• Previous treatment with dupilumab.
• Pregnant women (positive urine pregnancy test result at the screening visit or the baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study.
• History of, current, or suspected lymphoproliferative disease or malignancy of any organ system within the last 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the baseline visit.
• History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, i.e., monoclonal antibody) or to lidocaine.
• Known active or latent tuberculosis (TB) infection.
• Known or suspected immunosuppression or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment.
• History of or current confounding skin condition (i.e., active atopic dermatitis, chronic urticaria, psoriasis, cutaneous T-cell lymphoma \[mycosis fungoides or Sezary syndrome\], contact dermatitis, chronic actinic dermatitis, dermatitis herpetiformis).
• Planned or expected major surgical procedure during the clinical study.
• History of alcohol or substance abuse within 6 months of the screening.

Sponsors & Collaborators

• University of Michigan: lead
• Regeneron Pharmaceuticals: collaborator

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Exanthema

Interventions

dupilumab

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Mio Nakamura, MD, MS

  University of Michigan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Dermatology

Study Record Dates

• First Submitted: August 21, 2023
• First Posted: August 25, 2023
• Study Start: October 2, 2023
• Primary Completion: January 7, 2025
• Study Completion: March 25, 2025
• Last Updated: January 12, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)